Acuta Capital Partners, LLC Reata Pharmaceuticals Inc Transaction History

Acuta Capital Partners, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$25.61 - $110.96 $448,175 - $1.94 Million	-17,500 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$100.0 - $143.02 $750,000 - $1.07 Million	7,500 Added 75.0%	17,500 $1.76 Million
Q2 2021 Aug 16, 2021	SELL	$78.27 - $151.29 $313,080 - $605,160	-4,000 Reduced 28.57%	10,000 $1.42 Million
Q1 2021 May 17, 2021	BUY	$94.25 - $132.81 $1.32 Million - $1.86 Million	14,000 New	14,000 $1.4 Million
Q3 2020 Nov 16, 2020	SELL	$93.53 - $163.34 $1.43 Million - $2.5 Million	-15,300 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$126.3 - $176.56 $1.04 Million - $1.45 Million	-8,200 Reduced 34.89%	15,300 $2.39 Million
Q1 2020 May 15, 2020	SELL	$124.16 - $247.74 $1.8 Million - $3.59 Million	-14,500 Reduced 38.16%	23,500 $3.39 Million
Q4 2019 Feb 14, 2020	SELL	$74.57 - $217.92 $521,989 - $1.53 Million	-7,000 Reduced 15.56%	38,000 $7.77 Million
Q3 2019 Nov 14, 2019	BUY	$71.26 - $95.75 $3.21 Million - $4.31 Million	45,000 New	45,000 $3.61 Million

62.7K

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

Get notified when there are updates to the investment portfolio of Acuta Capital Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Acuta Capital Partners, LLC with notifications on news.